You are here:

Archived: desmopressin (Noqdirna)

Advice

following a full submission:

desmopressin (Noqdirna®) is not recommended for use within NHS Scotland.

Indication under review: Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.

Two phase III, placebo-controlled studies demonstrated that desmopressin, at licensed doses over three months, significantly reduced the mean number of nocturnal voids and resulted in higher proportions of responders compared with placebo, in patients with nocturia.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: desmopressin (Noqdirna)
SMC Drug ID: 1218/17
Manufacturer: Ferring Pharmaceuticals Ltd
Indication: symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
BNF Category:
Sub Category: 6.5 Hypothalamic and pituitary hormones and anti-oestrogens
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 February 2017

Current Advice

Resubmission 7 August 2017

Back